TUDCA is best known as a liver and bile acid supplement, but a small group of lung studies has tested it in mice with scarred lungs, allergic airways and dust-damaged tissue. The results are consistent in one direction: in a bleomycin model of pulmonary fibrosis, TUDCA reduced collagen deposition and markers of ER stress [1], and in a house dust mite model of allergic asthma it lowered airway inflammation and hyperresponsiveness [2]. A silica exposure study reported less inflammation and fibrosis and faster recovery of lung function [3]. All of this work was done in rodents, and no study has given TUDCA to people with a lung condition and measured breathing, scarring or symptoms. This page goes through what each study tested, how TUDCA was given, and where the evidence stops.
Key Takeaways
- In mice given bleomycin to scar the lungs, daily intraperitoneal TUDCA at 250 mg/kg reduced collagen deposition, epithelial-mesenchymal transition markers and the ER stress proteins GRP78 and CHOP [1].
- A second bleomycin study found that mice lacking the CHOP gene developed less fibrosis, and that TUDCA reduced fibrosis and inflammation in normal mice in a dose-dependent manner [4].
- In a house dust mite asthma model, TUDCA lowered airway inflammation, mucus metaplasia and airway hyperresponsiveness, but when given after the allergen phase it did not reverse airway remodeling [2].
- A comparison of six bile acids in the same asthma model found TUDCA and one other conjugated bile acid among the most effective, acting mainly through the ATF6α arm of the unfolded protein response [5].
- No human lung trial of TUDCA has been published. In the pulmonary hypertension study often cited alongside it, the prevention and reversal results were reported for a different chaperone, 4-phenylbutyrate [6].
Why ER Stress Comes Up in Lung Research
The cells lining the airways and the air sacs do a lot of protein work. They secrete mucus, surfactant and signaling molecules, and they repair themselves after injury from smoke, dust, infection and allergens. Proteins are folded in the endoplasmic reticulum, and when that folding falls behind demand, the cell switches on the unfolded protein response. If that response stays on, it can push the cell toward inflammation, scarring or death.
Researchers track this with markers such as GRP78, a chaperone that rises under strain, and CHOP, a transcription factor linked to stress-induced cell death and inflammation. In lung research, researchers want to know whether chronic ER stress helps drive conditions like pulmonary fibrosis and asthma, and whether easing it changes the course of disease. TUDCA is one of the standard chemical chaperones used to test that idea, which is why it shows up in these studies rather than because it was developed as a lung treatment.
The Pulmonary Fibrosis Studies
Bleomycin and epithelial-mesenchymal transition. Bleomycin is a chemotherapy drug that scars the lungs, and a single dose into the airway is a standard way to model pulmonary fibrosis in mice. In one study, mice received bleomycin and a daily intraperitoneal injection of TUDCA at 250 mg/kg [1]. TUDCA reduced the destruction of the alveolar walls, inflammatory cell infiltration and interstitial collagen deposition. It also blunted the shift of lung epithelial cells toward a scar-forming phenotype, measured as higher α-smooth muscle actin and lower E-cadherin, and it suppressed Smad2/3 signaling, oxidative stress markers and the ER stress proteins GRP78 and CHOP [1]. The authors described this as a pretreatment effect, so the study tested prevention, not the reversal of established scarring.
The role of CHOP. A second bleomycin study asked whether CHOP itself drives the damage [4]. Bleomycin raised CHOP in the lungs within the first days, and mice bred without the CHOP gene developed less fibrosis, fewer inflammatory cells in lung fluid and less cell death than normal mice. Giving TUDCA to normal mice reduced bleomycin-induced fibrosis, inflammation and the rise in CHOP, and the effect grew with dose [4]. The authors framed TUDCA as a possible strategy for preventing pulmonary fibrosis, not for treating it once established.
Idiopathic pulmonary fibrosis in people develops slowly and is usually diagnosed after scarring is well established. A model in which TUDCA is given at the same time as a single chemical injury is a long way from that situation, and neither abstract reports an effect on fibrosis that had already formed.
The Asthma and Allergic Airway Studies
House dust mite model. One group tested TUDCA in mice repeatedly exposed to house dust mite, a common human allergen [2]. They tried three schedules. Given during the allergen challenge, TUDCA decreased inflammation, ER stress markers, airway hyperresponsiveness and fibrosis. Given after the challenge phase, it decreased inflammation, mucus metaplasia, ER stress markers and hyperresponsiveness, but not airway remodeling. Given during a later rechallenge, it reduced all of these, including fibrotic remodeling [2]. The pattern suggests TUDCA acted on active inflammation more reliably than on structural changes that had already formed.
Comparing bile acids. A follow-up study compared five conjugated bile acids and one unconjugated bile acid in the same kind of house dust mite model [5]. TUDCA and alanyl β-muricholic acid were among the most effective at reducing inflammatory and immune responses, mucus metaplasia and airway hyperresponsiveness. The researchers found that these bile acids bound preferentially to ATF6α, one of the three sensors of the unfolded protein response, and that they worked without significantly activating the classic bile acid receptors. In airway brushings from people, several ATF6α-related transcripts were higher in patients with asthma than in healthy subjects [5]. That human part of the study measured gene activity in airway cells. It did not give TUDCA to anyone.
Silicosis and Intermittent Hypoxia
Silicosis is lung scarring caused by inhaled crystalline silica dust, an occupational disease of mining, stone cutting and construction. In a mouse silica model, TUDCA reduced pulmonary inflammation and fibrosis and helped lung function recover faster [3]. Most of the paper is about the immune mechanism: TUDCA reduced lung-resident memory T cells that produce interferon-γ and interleukin-17A, and it affected different regulatory T cell populations in different ways [3]. A corrigendum to this paper was published in 2026 [7]. The notice has no abstract, so it does not say what was corrected, which is one more reason to treat the specific mechanistic findings as provisional.
A smaller study exposed mice to four weeks of intermittent hypoxia, with oxygen cycling between 21% and 10% for eight hours a day, a pattern meant to resemble obstructive sleep apnea [8]. Intermittent hypoxia raised caspase-12, cleaved caspase-3, GRP78 and CHOP in lung tissue, and TUDCA reduced all of them, with eight mice per group [8]. The study measured markers of cell death in lung tissue. It did not measure breathing, sleep or oxygen levels, and the full paper is in Chinese, so only the English abstract was reviewed here.
Pulmonary Hypertension: Read the Details
A 2013 study in the journal Circulation is often cited when ER stress and pulmonary hypertension come up [6]. It is worth reading carefully. The animal results, in which treatment both prevented and reversed hypoxia-induced pulmonary hypertension in mice and was replicated in a rat model, came from 4-phenylbutyrate given in drinking water. TUDCA appears alongside 4-phenylbutyrate in the mechanism experiments: both chaperones improved ER stress indexes in vivo and in vitro and decreased ATF6 activation, and the abstract reports that the chaperones suppressed proliferation of pulmonary artery smooth muscle cells [6].
So this paper supports the idea that ER stress matters in pulmonary hypertension, and it shows TUDCA acting on the relevant cells. It does not report that TUDCA prevented or reversed pulmonary hypertension in an animal; those outcomes are reported for 4-phenylbutyrate. Pages that cite it as evidence for TUDCA and pulmonary hypertension are claiming more than the abstract reports.
What This Means if You Have a Lung Condition
Taken together, these studies support a narrow conclusion. ER stress markers rise in several mouse models of lung injury, and TUDCA reduced those markers along with inflammation and scarring in the models tested. In the asthma work, its effects were clearer on active inflammation than on airway remodeling [2]. Whether a TUDCA capsule reaches the lungs in useful amounts, and whether it changes breathing, flare-ups or scarring in people, has not been studied.
Asthma, pulmonary fibrosis, silicosis and pulmonary hypertension all have established treatments that have been tested in people, and several of them can become dangerous quickly. A supplement with only rodent support is not a substitute for prescribed inhalers or antifibrotic therapy. If you are considering TUDCA, the reasonable approach is to treat it as an unproven add-on, raise it with the clinician managing your lung condition, and never reduce prescribed medication because of it.
Bottom Line
In mice, TUDCA reduced bleomycin-induced lung fibrosis and ER stress [1], with a dose-dependent effect tied to CHOP [4], and it lowered airway inflammation and hyperresponsiveness in a house dust mite asthma model [2]. It reduced inflammation and fibrosis after silica exposure [3] and lowered ER stress markers after intermittent hypoxia [8]. Every result is from rodents or cells, the one fibrosis abstract that states a route used injection, and the pulmonary hypertension prevention result belongs to a different chaperone [6]. There is no human trial of TUDCA for any lung condition.
Frequently Asked Questions
Does TUDCA help pulmonary fibrosis?
It has only been tested in mice. Given alongside bleomycin, injected TUDCA reduced collagen deposition and ER stress markers [1] and reduced fibrosis in a dose-dependent way [4]. Both studies tested prevention at the time of injury, not the reversal of existing scarring, and no human trial exists.
Can TUDCA help with asthma?
In mouse models of house dust mite allergy, TUDCA reduced airway inflammation, mucus metaplasia and airway hyperresponsiveness [2], and it was among the more effective bile acids in a head-to-head comparison [5]. No study has given TUDCA to people with asthma, so it should not replace any prescribed asthma treatment.
Is TUDCA proven for pulmonary hypertension?
No. In the main study on ER stress and pulmonary hypertension, the animal prevention and reversal results came from 4-phenylbutyrate. For TUDCA, the abstract reports improved ER stress indexes and lower ATF6 activation, not pulmonary pressure or vascular remodeling outcomes [6].
References
- Tong B, et al. Tauroursodeoxycholic acid alleviates pulmonary endoplasmic reticulum stress and epithelial-mesenchymal transition in bleomycin-induced lung fibrosis. BMC Pulmonary Medicine (2021). PMID 33952237
- Siddesha JM, et al. Effect of a chemical chaperone, tauroursodeoxycholic acid, on HDM-induced allergic airway disease. American Journal of Physiology. Lung Cellular and Molecular Physiology (2016). PMID 27154200
- Li C, et al. Tauroursodeoxycholic acid (TUDCA) disparate pharmacological effects to lung tissue-resident memory T cells contribute to alleviated silicosis. Biomedicine and Pharmacotherapy (2022). PMID 35623165
- Tanaka Y, et al. The exacerbating roles of CCAAT/enhancer-binding protein homologous protein (CHOP) in the development of bleomycin-induced pulmonary fibrosis and the preventive effects of tauroursodeoxycholic acid (TUDCA) against pulmonary fibrosis in mice. Pharmacological Research (2015). PMID 26005208
- Nakada EM, et al. Conjugated bile acids attenuate allergen-induced airway inflammation and hyperresponsiveness by inhibiting UPR transducers. JCI Insight (2019). PMID 31045581
- Dromparis P, et al. Attenuating endoplasmic reticulum stress as a novel therapeutic strategy in pulmonary hypertension. Circulation (2013). PMID 23149668
- Li C, et al. Corrigendum to: Tauroursodeoxycholic acid (TUDCA) disparate pharmacological effects to lung tissue-resident memory T cells contribute to alleviated silicosis. Biomedicine and Pharmacotherapy (2026). PMID 42209344
- Shi Z, et al. Tauroursodeoxycholic acid suppresses endoplasmic reticulum stress in pulmonary tissues of intermittent hypoxia mice. Journal of Central South University. Medical Sciences (2015). PMID 26643417
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
